Clinical use of hematopoietic growth factors in the myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 26, Issue SUPPL. 1, 1997, Pages 13-27

  Ganser, A ^a   Karthaus, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTARABINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; RETINOIC ACID;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALLOGRAFT; ANEMIA; BLEEDING; BLOOD CELL COUNT; BLOOD TOXICITY; BONE PAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPENIA; ERYTHEMA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEVER; HEADACHE; HUMAN; INFECTION RISK; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL; PANCYTOPENIA; PRIORITY JOURNAL; REFRACTORY ANEMIA; SPLENOMEGALY; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0031462140     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058596     Document Type: Conference Paper

References (157)

1. Ganser, A. and Hoelzer, D. (1992). Clinical course of myelodysplastic syndromes. Hematol/Oncol Clin North Amer, 6, 607-618.
2. Hoelzer, D., Ganser, A. and Heimpel, H. (1984). "Atypical" leukemias: preleukemia, smoldering leukemia and hypoplastic leukemia. Rec Res Cancer Res, 93, 69-101.
3. Bennett, J. M., Catovsky, D., Daniel, M., et al. (1982). Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 51, 189-199.
4. Jacobs, A. (1991). Genetic lesions in preleukemia. Leukemia, 5, 277-282.
5. Prchal J. T., Trockmorton, D. W., Carrol, A. J., et al. (1978). A common progenitor for myeloid and lymphoid cells. Nature, 274, 590-591.
6. Raza, A., Gezer, S., Mundle, S., et al. (1995). Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268-276.
7. Raza, A., Mundle, S., Iftikhar, A., et al. (1995). Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol, 48, 143-154.
8. Bartram, C. R. (1992). Molecular genetic aspects of myelodysplastic syndromes. Hematol/Oncol Clin North Amer, 6, 557-570.
9. van Kamp, H., de Pijper, C., Verlaan-de Vries, M., et al. (1992). Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood, 79, 1266-1270.
10. Paquette, R. L., Landaw, E. M., Pierre, R. V., et al. (1993). N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood, 82, 590-599.
11. van Kamp, H., Fibbe, W. E., Jansen, R. P. M., et al. (1992). Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood, 1774-1780.
12. Janssen, J. W. G., Buschle, M., Layton, M., et al. (1989). Clonal analysis of myelodysplastic syndromes: evidence of multipotential stem cell origin. Blood, 73, 248-254.
13. Hoefsloot, L. H., van Amelsvoort, M. P., Broeders, C. C. A. M., Backx, B., van der Plas, D. C., Touw, I. P. and Löwenberg, B. (1995). Impaired erythropoiesis in myelodysplastic syndrome is associated with the inability of erythropoietin receptor to activate STAT-5. Blood, 86, Suppl 1, 271A.
14. Aul, C., Arning, M., Runde, V. and Schneider, W. (1991). Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res, 15, 571-575.
15. Bowen, D. T., Jacobs, A., Cotes, M. P., et al. (1990). Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. Eur J Haematol, 44, 30-32.
16. Jacobs, A., Janowska-Wieczorek, A., Caro, J., et al. (1989). Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol, 73, 36-39.
17. Verhoef, G. E., De Schouwer, P., Ceuppens, J. L., et al. (1992). Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia, 6, 1268-1272.
18. Völkers, B., Ganser, A., Greher, J., et al. (1989). Effect of tumor necrosis factor-alpha on human hematopoietic progenitor cells. Onkologie, 12, 109-115.
19. Ohmori, S., Ohmori, M., Yamagishi, M. and Okuma, M. (1993). MDS-macrophage derived inhibitory activity on myelopoiesis of MDS abnormal clones. Br J Haematol, 83, 388-391.
20. Aul, C., Gattermann, N. and Schneider, W. (1992). Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol, 82, 358-367.
21. Williamson, P. J., Kruger, A. R., Reynolds, P. J., et al. (1994). Establishing the incidence of myelodysplastic syndrome. Br J Haematol, 87, 743-745.
22. Blank, J. and Lange, B. (1981). Preleukemia in children. J Pediatr, 98, 565-.
23. Aul, C. and Schneider, W. (1983). Myelodysplastic syndromes. A prognostic factor analysis of 221 untreated patients. Blut, 57, 234-.
24. Mufti, G. J., Stevens, J. R., Oscier, D. G., et al. (1985). Myelodysplastic syndromes. A scoring system with prognostic significance. Br J Haematol, 59, 425-.
25. Sanz, G. F., Sanz, M. A., Vallespi, T., et al. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395-.
26. Tricot, G., Criel, A. and Verwilghen, R. L. (1982). Thrombocytopenia as presenting symptom of preleukaemia in 3 patients. Scand J Haematol, 28, 243-.
27. Mufti, G. J. and Galton, D. A. G. (1986). Myelodysplastic syndromes. Natural history and features of prognostic significance. Clin Haematol, 15, 953-.
28. Boogaerts, M. A., Nelissen, V., Roelant, C. and Goossens, W. (1983). Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol, 55, 217-.
29. Schofield, K. P., Stone, P. C. W., Kelsey, P., et al. (1983). Quantitative cytochemistry of blood neutrophils in myelodysplastic syndromes and chronic granulocytic leukemia. Cell Biochem Function, 1, 92-.
30. Scott, C. S., Cahill, A., Bynoe, A. G., et al. (1983). Esterase cytochemistry in primary myelodysplastic syndromes and megaloblastic anaemias: Demonstration of abnormal staining patterns associated with dysmyelopoiesis. Br J Haematol, 55, 411-.
31. Fenaux, P., Jouet, J. P., Zandecki, M., et al. (1987). Chronic and subacute myelomonocytic leukaemia in the adult. A report of 60 cases with special references to prognostic features. Br J Haematol, 65, 101-.
32. Ribera, J. M., Cervantes, F. and Rozman, C. A. (1987). A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. Br J Haematol, 65, 307-.
33. Lintula, R., Rasi, V., Ikkala, E., et al. (1981). Platelet function in preleukaemia. Scand J Haematol, 96, 65-.
34. Maldonado, J. E. and Pierre, R. V. (1975). The platelets in preleukemia and myelomonocytic leukemia: Ultrastructural cytochemistry and cytogenetics. Mayo Clin Proc, 50, 573-.
35. Cazzola, M., Barosi, C., Gobbi, P. G., et al. (1988). Natural history of idiopathic refractory sideroblastic anemia. Blood. 71, 305-.
36. Gattermann, N., Aul, C. and Schneider, W. (1990). Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol, 74, 45-.
37. Streeter, R. R., Presant, C. A. and Reinhard, E. (1977). Prognostic significance of thrombocytosis in idiopathic sideroblastic anemia. Blood, 50, 427-.
38. Kerkhofs, H., Hermans, I., Haak, H. L. and Leeksma, C. H. W. (1987). Utility of the FAB classification for myelodysplastic syndromes. Investigation of prognostic factors in 237 cases. Br J Haematol, 65, 73-.
39. Tricot, G., Vlietinck, R., Boogaerts, M. A., et al. (1985). Prognostic factors in the myelodysplastic syndromes. Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol, 60, 19-.
40. Varela, G. L., Chuang, C., Woll, J. E. and Bennett, J. M. (1985). Modifications in the classification of primary myelodysplastic syndromes. The addition of a scoring system. Haematol Oncol, 3, 55-.
41. Pomeroy, C., Oken, M. M., Rydell, R. E. and Filice, G. A. (1991). Infection in the myelodysplastic syndromes. Am J Med, 90, 338-.
42. Mecucci, C. and van den Berghe, H. (1992). Cytogenetics. Hematol/Oncol Clin North Amer, 6, 523-541.
43. Richert-Boe, K. E. and Bagby, G. C. (1992). In vitro hematopoiesis in myelodysplasia: liquid and soft-gel culture studies. Hematol/Oncol Clin North Amer, 6, 543-556.
44. Tennant, G. B., Bowen, D. T. and Jacobs, A. (1991). Colony-cluster ratio and cluster number in cultures of circulating myeloid progenitors as indicators of high-risk myelodysplasia. Br J Haematol, 77, 296-300.
45. Löffler, H., Schmitz, N. and Gassmann, W. (1992). Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Hematol/Oncol Clin North Amer, 6, 619-632.
46. Paquette, R. L. and Koeffler, H. P. (1992). Differentiation therapy. Hematol/Oncol Clin North Amer, 6, 687-706.
47. Anderson, J. E., Appelbaum, F. R., Fisher, L. D., et al. (1993). Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood, 82, 677-681.
48. Dührsen, U. and Hossfeld, D. (1994). Hematopoietic growth factors and the treatment of tumor-associated anemias. Ann Hematol, 69, 213-221.
49. Ganser, A. and Hoelzer, D. (1992). Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol/Oncol Clin North Amer, 6, 633-654.
50. Ganser, A. (1995). Hematopoietic growth factors in the treatment of myelodysplastic syndromes. Curr Opinion Hematol, 2, 204-209.
51. Legare, R. D. and Gilliland, D. G. (1995). Myelodysplastic syndrome. Curr Opinion Hematol, 2, 283-292.
52. Löwenberg, B. and Touw, I. P. (1993). Hematopoietic growth factors and their receptors in acute leukemia. Blood, 81, 281-292.
53. Negrin, R. S., Haeuber, D. H., Nagler, A., et al. (1990). Maintenance therapy of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood, 76, 36-43.
54. Kobayashi, Y., Okabe, T., Ozawa, K., et al. (1989). Treatment of myelodysplastic syndromes with human granulocyte colony-stimulating factor: a preliminary report. Am J Med, 86, 178-182.
55. Negrin, R. S., Stein, R., Vardiman, J., et al. (1993). Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood, 82, 737-743.
56. Yuo, A., Kitagawa, S., Okabe, T., et al. (1987). Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia. Blood, 70, 404-411.
57. Greenberg, P., Taylor, K., Larson, R., et al. (1993). Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood, 82, Suppl 1, 196a.
58. Greenberg, P., Negrin, R., Nagler, A., et al. (1990). Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Int J Cell Cloning, 8, Suppl 1, 293-302.
59. Negrin, R., Haeubre, D. H., Nagler, A., et al. (1989). Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I/II trial. Ann Intern Med, 110, 976-984.
60. Yoshida, Y., Hirashima, K., Asano, S., et al. (1991). A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol, 78, 378-384.
61. Ganser, A., Seipelt, G., Verbeeck, W., et al. (1994). Effect of combination therapy with all-trans retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia, 8, 369-375.
62. Aul, C., Runde, V. and Gattermann, N. (1993). All-rans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood, 82, 1967-1974.
63. Kurzrock, R., Estey, E. and Talpaz, M. (1993). All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndromes. J Clin Oncol, 11, 1489-1496.
64. Ohno, R., Naoe, T., Hirano, M., et al. (1993). Treatment of myelodysplastic syndromes with all-trans retinoic acid. Blood, 81, 1152-1154.
65. Visani, G., Cenacchi, A., Tosi, P., et al. (1992). All-trans retinoic acid improves erythropoiesis in myelodysplastic syndromes: a case report. Br J Haematol, 81, 444-448.
66. Maurer, A. B., Ganser, A., Seipelt, G., et al. (1995). Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haematopoietic growth factors. Br J Haematol, 89, 449-456.
67. Kurzrock, R., Talpaz, M., Gomez, J. A., et al. (1991). Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low-over high-dose administration in selected patients. Br J Haematol, 78, 352-358.
68. Rose, C., Wattel, E., Bastion, Y., et al. (1994). Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia, 8, 1458-1462.
69. Schuster, M. W., Thompson, J. A., Larson, R., et al. (1995). Randomized phase II study of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS). Blood, 86, Suppl 1, 338a.
70. Delmer, A., Karmochkine, M., Cadiou, M., et al. (1990). Recurrent spleen enlargement during cyclic granulocyte-macrophae colony-stimulating factor therapy for myelodysplastic syndromes. Am J Hematol, 34, 73-74.
71. Wilson, P. A., Ayscue, L. H., Jones, G. R., et al. (1993). Bone marrow histiocytic proliferation in association with colony-stimulating factor therapy. Am J Clin Pathol, 99, 311-313.
72. Antin, J. H., Smith, B. R., Holmes, W., et al. (1988). Phase I/II study of recombinant human granulocyte-macrophage colony stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood, 72, 705-713.
73. Ganser, A., Völkers, B., Greher, J., et al. (1989). Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes - a phase I/II trial. Blood, 73, 31-37.
74. Rosenfeld, C. S., Sulecki, M., Evans, C., et al. (1991). Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol, 19, 273-277.
75. Thompson, J. A., Douglas, J. L., Kidd, P., et al. (1989). Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics. and hematological effects. J Clin Oncol, 7, 629-637.
76. Vadhan-Raj, S., Kellagher, M. J., Keating, M., et al. (1988). Phase I study of recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndrome. N Engl J Med, 317, 1545-1552.
77. Maurer, A. B., Ganser, A., Buhl, R., et al. (1993). Restoration of impaired cytokine secretion from patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia, 7, 189-195.
78. Bhalla, K., Birkhofer, M., Arlin, Z., et al. (1988). Effect of recombinant GM-CSF and IL-3 on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia, 2, 810-813.
79. Brach, M., Klein, H., Platzer, E., et al. (1990). Effect of interleukin-3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Hematol, 18, 748-753.
80. Ganser, A., Seipelt, G., Eder, M., et al. (1992). Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol, 19, Suppl 4, 95-101.
81. Van der Lely, N., De Witte, T., Muus, P., et al. (1991). Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp Hematol, 19, 267-272.
82. Ganser, A., Ottmann, O. G., Schulz, G., et al. (1989). Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study. Onkologie, 12, 13-15.
83. Höffken, K., Overkamp, F., Stirbu, J., et al. (1990). Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie, 13, 33-37.
84. Hoelzer, D., Ganser, A., Ottmann, O. G., et al. (1990). Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes. Haematol Blood Transfusion, 33, 763-769.
85. Gerhartz, H. H., Marcus, R., Delmer, A., et al. (1994). A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia, 8, 16-23.
86. Cheson, B. D. and Simon, R. (1987). Low dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years experience. Sem Oncol, 14, Suppl 1, 126-133.
87. Ganser, A., Lindemann, A., Seipelt, G., et al. (1990). The effect of recombinant human interleukin-3 in patients with normal hemopoiesis and in patients with secondary bone marrow failure. Blood, 76, 666-676.
88. Bernstein, S. F., Gilliland, D. G., Aster, J., et al. (1992). A randomized trial of two doses of recombinant interleukin-3 in patients with myelodysplastic syndrome. Blood, 80, Suppl. 1, 410a.
89. Dunbar, C. E., Smith, D., Kimball, J., et al. (1990). Sequential treatment with recombinant human growth factors to compare activity of GM-CSF and IL3 in the treatment of primary myelodysplasia. Blood, 76, Suppl 1, 141a.
90. Ganser, A., Seipelt, G., Lindemann, A., et al. (1990). Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood, 76, 455-462.
91. Ganser, A., Ottmann, O. G., Seipelt, G., et al. (1993). Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia, 7, 696-701.
92. Kurzrock, R., Talpaz, M., Estrov, Z., et al. (1991). Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol, 9, 1241-1250.
93. Nimer, S. D., Pacquette, R. L., Ireland, P., et al. (1994). A phase I/II study of the interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol, 22, 875-880.
94. Seipelt, G., Ganser, A., Duranceyk, H., et al. (1994). Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. Ann Hematol, 68, 167-170.
95. Zwierzina, H., Herold, M., Geiller, D., et al. (1991). Soluble interleukin-2 (IL-2) receptor expression in patients with myelodysplastic syndromes is induced by granulocyte-macrophage colony-stimulating factor and IL-3. Blood, 77, 2795-2796.
96. Seipelt, G., Ganser, A., Duranceyk, H., et al. (1993). Induction of TNF-α in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol, 84, 749-751.
97. Gordon, M. S., Nemunaitis, J., Hoffman, R., et al. (1995). A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood, 85, 3066-3076.
98. Bowen, D., Ehmer, B., Neubert, P., et al. (1991). The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol, 19, 613-616.
99. Hellström-Lindberg, E. (1995). Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol, 89, 67-71.
100. Broxmeyer, H. E., Cooper, S., Williams, D. E., et al. (1988). Growth characteristics of marrow hematopoietic progenitor/ precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyt-macrophage colony-stimulating factor. Exp Hematol, 16, 594-602.
101. Vadhan-Raj, S., Broxmeyer, H. E., Spitzer, G., et al. (1989). Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood, 74, 1491-1498.
102. Ottmann, O. G., Ganser, A., Seipelt, G., et al. (1990). Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood, 76, 1494-1502.
103. Rafanelli, D., Grossi, A., Longo, G., et al. (1992). Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia, 6, 323-327.
104. Schouten, H. C., Vellenga, E., van Rhenen, D. J., et al. (1991). Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia, 5, 432-436.
105. Van Kamp, H., Tineke, C., Prinsze-Postema, T. C., et al. (1991). Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol, 78, 488-493.
106. Verhoef, G., Van Den Berghe, H. and Boogaerts, M. (1992). Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hematopoietic growth factors. Leukemia, 6, 766-769.
107. Anastasi, J., Feng, J., LeBeau, M. M., et al. (1993). Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridizytion: Lineage, response to growth factor therapy and clonal expansion. Blood, 81, 1580-1585.
108. Ohyashiki, K., Ohyashiki, J. H., Toyama, K., et al. (1989). Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor. Jpn J Cancer Res, 80, 848-854.
109. Ganser, A., Janssen, J. W. G., Ottmann, O. G., et al. (1991). In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders. Leukemia, 5, 487-492.
110. Hellström-Lindberg, E., Birgegard, G., Carlsson, M., Dah, et al. (1993). A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma, 11, 221-228.
111. Imamura, M., Kobayashi, M., Kobayashi, S., et al. (1994). Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol, 68, 163-166.
112. Ohio, R., Balleari, E., Ballestrero, A., et al. (1993). Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol, 90, 58-64.
113. Hansen, P. B., Hippe, E., Hellström-Lindberg, E., et al. (1993). Recombinant human granulocytemacrophage colony-stimulating factor plus erythropoietin may improve anemia in selected patients with myelodysplasia. Am J Hematol, 44, 229-236.
114. List, A. L., Noyes, W., Power, J., et al. (1993). Combined treatment of myelodysplastic syndromes (MDS) with recombinant human interleukin-3 (IL-3) and erythropoietin (EPO). Blood, 82, Suppl 1, 377a.
115. Verhoef, G., Demuynck, H., Zachée, P., et al. (1993). Treatment of myelodysplastic syndromes (MDS) with the combination of interleukin-3 and erythropoietin. Blood, 82, Suppl 1, 377a.
116. Ganser, A., Lindemann, A., Ottmann, O. G., et al. (1992). Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis. Blood, 79, 2583-2591.
117. Nand, S., Sosman, J., Godwin, J. E., et al. (1994). A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood, 83, 357-360.
118. Ganser, A., Maurer, A., Contzen, C., et al. (1996). Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with alltrans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin, and α-tocopherol. Ann Hematol, 72, 237-244.
119. Dombret, H., Chastang, C., Fenaux, P., et al. (1995). A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med, 332, 1678-1683.
120. Ohno, R., Tomonaga, M., Kobayashi, T., et al. (1990). Effect of granulocyte-colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med, 323, 871-877.
121. Rowe, J. M., Andersen, J., Mazza, J., et al. (1995). A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia. A study of the Eastern Cooperative Oncology Group (E 1490). Blood, 86, 457-462.
122. Stone, R., Berg, D. T., George, S. L., et al. (1995). Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med, 332, 1671-1677.
123. Ganser, A., Heil, G., Kolbe, K., et al. (1993). Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia - initial results. Ann Hematol, 66, 123-125.
124. Demuynck, H., Delforge, M., Verhoef, G. E. G., et al. (1996). Feasability of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol, 92, 351-359.
125. Delforge, M., Demuynck, H., Vandenberghe, P., et al. (1995). Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood, 86, 3660-3667.
126. Estey, E. H., Kurzrock, R., Talpaz, M., et al. (1991). Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol, 77, 291-295.
127. Estey, E. H., Thall, P., Andreef, M., et al. (1994). Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol, 12, 671-678.
128. Bernell, P., Kimby, E. and Hast, R. (1994). Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia, 8, 1631-1639.
129. Kaczmarski, R. S. and Mufti, G. J. (1993). Low-dose filgrastim therapy for chronic neutropenia. N Engl J Med, 329, 1280-1281.
130. Yoshida, Y., Nakahata, T., Shibata, A., et al. (1995). Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. Leuk Lymphoma, 18, 457-463.
131. Herrmann, F., Lindemann, A., Klein, H., et al. (1989). Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia, 3, 335-338.
132. Willemze, R., Visani, G., de Witte, Th., et al. (1990). A randomized phase I/II study with recombinant human GM-CSF in patients (pts) with myelodysplastic syndromes at a relatively low risk of developing acute leukemia. Blood, 76. Suppl 1, 337a.
133. Gradishar, W. J., LeBeau, M. M., O'Laughlin, R., et al. (1992). Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood, 80, 2463-2470.
134. Takahasha, M., Yoshida, Y., Kaku, K., et al. (1993). Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia. Acta Haematol, 89, 189-194.
135. Bessho, M., Jinnai, I., Matsuda, A., et al. (1990). Improvement of anemia by recombinant human erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning, 8, 445-458.
136. Oster, W., Krumwieh, D., Brune, T., et al. (1990). Evaluation of erythropoietin (EPO) in the treatment of patients with myelodysplastic syndromes (MDS)-preclinical data supporting a rationale for sequential therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) and EPO. J Cancer Clin Oncol, 116, Suppl, 280.
137. Stebler, C., Tichelli, A., Dazzi, H., et al. (1990). High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Hematol, 18, 1204-1208.
138. Bowen, D., Culligan, D. and Jacobs, A. (1991). The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol, 77, 419-423.
139. Hellström, E., Birgegard, G., Locker, D., et al. (1991). Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol, 47, 355-360.
140. Stein, R. S., Abels, R. I. and Krantz, S. B. (1991). Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood, 78, 1658-1663.
141. Kurzrock, R., Talpaz, M., Estey, E., et al. (1991). Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia, 5, 985-990.
142. Verhoef, G. E., Zachee, P., Ferrant, A., et al. (1992). Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Hematol, 64, 16-21.
143. Shepherd, J. D., Currie, C. J., Sparling, T. G., et al. (1992). Erythropoietin therapy of myelodysplastic syndromes. Blood, 79, 1891-1892.
144. Cazzola, M., Ponchio, L., Beguin, Y., et al. (1992). Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: Results of a phase I/II clinical trial. Blood, 79, 29-37.
145. Goy, A., Belanger, C, Casadevall, N., et al. (1993). High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol, 84, 232-237.
146. Ludwig, H., Fritz, E., Leitgeb, C., et al. (1993). Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol, 4, 161-167.
147. Yoshida, Y., Anzai, N., Kawabata, H., et al. (1993). Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. Ann Hematol, 66, 175-180.
148. Zeigler, Z. R., Jones, D., Rosenfeld, C. S., et al. (1993).
149. Stenke, L., Wallvik, J., Celsing, F., et al. (1993). Prediction of response to treatment with recombinant erythropoietin in myelodysplastic syndromes. Leukemia, 7, 1324-1327.
150. Shapiro, S., Gershon, H., Rosenbaum, H., et al. (1993). Characterization of circulating erythrocytes from myelodysplastic patients treated with recombinant human erythropoietin. Leukemia, 7, 1328-1333.
151. Razzano, M., Caslini, C., Cortellazzo, S., et al. (1992). Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes. Br J Haematol, 81, 628-630.
152. Aloe Spiriti, M. A., Petti, M. C., Latagliata, R., et al. (1993). Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile? Leuk Lymphoma, 9, 79-83.
153. Mohr, B., Herrmann, R. and Huhn, D. (1993). Recombinant human erythropoietin in patients with myelodysplastic syndromes and myelofibrosis. Acta Haematol, 90, 65-70.
154. Isnard, F., Najman, A., Jaar, B., et al. (1994). Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leuk Lymphoma, 12, 307-314.
155. Stone, R. M., Bernstein, S. H., Demetri, G., et al. (1994). Treatment with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res, 18, 769-776.
156. Rose, E. H., Abels, R. I., Nelson, R. A., et al. (1995). The use of r-HuEpo in the treatment of anemia related Ito myelodysplasia (MDS). Br J Haematol, 89, 831-837.
157. Backx, B., Broeders, L., Touw, I. and Löwenberg, B. (1993). Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia, 7, 75-79.